Company intelligence / Profile preview

Byondis

Nijmegen, Gelderland, Netherlandsbyondis.com ↗

Ownership: Private
Employees: ~350
Development stage: Phase 3

Overview

Byondis has a wholly owned pipeline of next-generation ADCs and mAbs targeting validated cancer antigens. Lead programs are advancing through early clinical trials with a focus on improved selectivity, efficacy, and safety profiles. The company leverages proprietary linker-payload technologies to optimize therapeutic windows.

Therapeutic areas: OphthalmologyHematologyOncology
Modalities: Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)Small molecules
Industry: Biotech

Drug pipeline

7 assets

trastuzumab duocarmazine

6 more assets in the full pipeline.

Request access →

Partnerships

Open to collaborations with research institutions and biopharmaceutical companies but no specific major partnerships disclosed as of now.

Beyond the preview

Go deeper on Byondis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Byondis.

Explore the full profile